Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington, KY 40536-0082, USA.
Nanomedicine (Lond). 2010 Jun;5(4):597-615. doi: 10.2217/nnm.10.35.
Multidrug resistance (MDR) is a major impediment to the success of cancer chemotherapy. P-glycoprotein is an important and the best-known membrane transporter involved in MDR. Several strategies have been used to address MDR, especially P-glycoprotein-mediated drug resistance in tumors. However, clinical success has been limited, largely due to issues regarding lack of efficacy and/or safety. Nanoparticles have shown the ability to target tumors based on their unique physical and biological properties. To date, nanoparticles have been investigated primarily to address P-glycoprotein and the observed improved anticancer efficacy suggests that nanomedicinal strategies provide a new opportunity to overcome MDR. This article focuses on nanotechnology-based formulations and current nanomedicine approaches to address MDR in tumors and discusses the proposed mechanisms of action.
多药耐药(MDR)是癌症化疗成功的主要障碍。P-糖蛋白是一种重要且最著名的参与 MDR 的膜转运蛋白。已经使用了多种策略来解决 MDR 问题,特别是针对肿瘤中 P-糖蛋白介导的药物耐药性。然而,临床应用的成功受到限制,主要是因为疗效和/或安全性方面的问题。纳米颗粒已经显示出基于其独特的物理和生物学特性靶向肿瘤的能力。迄今为止,主要研究纳米颗粒来解决 P-糖蛋白问题,并且观察到的抗癌疗效提高表明纳米药物策略为克服 MDR 提供了新的机会。本文重点介绍基于纳米技术的制剂和当前用于解决肿瘤中 MDR 的纳米医学方法,并讨论了拟议的作用机制。